Richard Klausner - 21 Jun 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Executive Chairman, Director
Signature: /s/ Heather Turner, as Attorney-in-fact
Issuer symbol: LYEL
Transactions as of: 21 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 23 Jun 2021, 17:36:41 UTC
Previous filing: 16 Jun 2021
Next filing: 27 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Conversion of derivative security		+3,765,842			3,765,842	21 Jun 2021	Lyell Investors, LLC	F1, F2
holding	LYEL	Common Stock						2,967,834	21 Jun 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-3,765,842	-100%	$0.000000^*	0	21 Jun 2021	Common Stock	3,765,842		Lyell Investors, LLC	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.
F2	The Reporting Person is a manager of Lyell Investors, LLC (Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein